Psyence Biomedical Ltd. (PBM)
NASDAQ: PBM · Real-Time Price · USD
6.32
+0.50 (8.59%)
At close: Sep 17, 2026, 4:00 PM EDT
6.40
+0.08 (1.27%)
After-hours: Sep 17, 2026, 7:45 PM EDT
Psyence Biomedical Employees
Psyence Biomedical had 12 employees as of March 31, 2025.
Employees
12
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$578,035
Market Cap
24.11M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 138 |
| NextCure | 40 |
| Atossa Therapeutics | 16 |
| Lantern Pharma | 16 |
| Actuate Therapeutics | 12 |
| Cellectar Biosciences | 11 |
| Cocrystal Pharma | 10 |
| Polyrizon | 4 |
PBM News
- 3 days ago - Psyence Biomedical establishes Texas Ibogaine Research Corporation - TheFly
- 3 days ago - Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development - GlobeNewsWire
- 22 days ago - Psyence Biomedical files to sell 1.15M common shares for holders - TheFly
- 4 weeks ago - Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development - GlobeNewsWire
- 3 months ago - Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform - Business Wire
- 4 months ago - Psyence Biomedical announces U.S. engagement initiative focused on ibogaine - TheFly
- 4 months ago - Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing - GlobeNewsWire
- 4 months ago - Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder - GlobeNewsWire